СОВРЕМЕННЫЕ ТЕХНОЛОГИИ ЯДЕРНОЙ МЕДИЦИНЫ В ДИАГНОСТИКЕ ОПУХОЛЕЙ ГОЛОВНОГО МОЗГА (ОБЗОР ЛИТЕРАТУРЫ)

В обзоре представлен анализ литературы, посвященной диагностике опухолей головного мозга и изучению их структурных и биологических особенностей на базе использования современных технологий ядерной медицины: однофотонной эмиссионной компьютерной томографии (ОФЭКТ) и позитронно-эмиссионной томографии, совмещенной с компьютерной томографией (ПЭТ-КТ) с различными РФП (радиофармацевтическими препаратами), в первую очередь, мечеными аминокислотами, такими как 11С-L-метионин и 18F-фтор-этилтирозин. Показано, что с помощью данных, полученных этими методами, особенно ПЭТ-КТ с меченными аминокислотами, могут быть неинвазивным путем изучены важнейшие биохимические процессы, лежащие в основе онкогенеза. Эти данные имеют решающее значение для раннего выявления опухолевого поражения, определения степени злокачественности опухоли, стадирования патологического процесса, обоснования лечебной тактики, персонализации лечения, оценки эффективности терапии в ранние сроки и прогнозирования исхода заболевания.

1. Rasmussen BK, Hansen S, Laursen RJ et al. Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry. J Neurooncol. 2017;135(3):571-579.

2. Tabouret E, Bauchet L, Carpentier AF. Brain metastases epidemiology and biology. Bull Cancer. 2013;100(1):57-62.

3. de Robles P, Fiest KM, Frolkis AD et al. The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. Neuro Oncol. 2015;17(6):776-83.

4. Inubushi M, Tatsumi M, Yamamoto Y et al. European research trends in nuclear medicine. Ann Nucl Med. 2018;32(9):579-582.

5. Karpuz M, Silindir-Gunay M, Ozer AY. Current and Future Approaches for Effective Cancer Imaging and Treatment. Cancer Biother Radiopharm. 2018;33(2):39-51.

6. Mabray MC, Barajas RF Jr, Cha S. Modern brain tumor imaging. Brain Tumor Res Treat. 2015;3(1):8-23.

7. Livieratos L. Technical pitfalls and limitations of SPECT/CT. Semin Nucl Med. 2015;45(6):530-40.

8. Le Jeune FP, Dubois F, Blond S, Steinling M. Sestamibi technetium-99m brain single-photon emission computed tomography to identify recurrent glioma in adults: 201 studies. J Neurooncol. 2006;77(2):177-83.

9. Cecchin D, Chondrogiannis S, Della Puppa A et al. Presurgical 99mTc-sestamibi brain SPET/CT versus SPET: a comparison with MRI and histological data in 33 patients with brain tumours. Nucl Med Commun. 2009;30(9):660-8.

10. Shibata Y, Yamamoto T, Takano S et al. Direct comparison of thallium-201 and technetium-99m MIBI SPECT of a glioma by receiver operating characteristic analysis. J Clin Neurosci. 2009;16(2):264-9.

11. Woesler B, Kuwert T, Morgenroth C et al. Noninvasive grading of primary brain tumours: results of a comparative study between SPET with 123I-α-methyl tyrosine and PET with 18F-deoxyglucose. Eur J Nucl Med. 1997;24(4):428-34.

12. Kuczer D, Feussner A, Wurm R et al. 123I-IMT SPECT for evaluation of the response to radiation therapy in high grade gliomas: a feasibility study. Br J Radiol. 2007;80(952):274-8.

13. Vander Borght T, Asenbaum S, Bartenstein P et al. EANM Procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging. 2006;33(11):1374-80.

14. Grosu AL, Feldmann H, Dick S et al. Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas. Int J Radiat Oncol Biol Phys. 2002;54(3):842-54.

15. Samnick S, Hellwig D, Bader JB et al. Initial evaluation of the feasibility of single photon emission tomography with p-[123I]iodo-L-phenylalanine for routine brain tumour imaging. Nucl Med Commun. 2002;23(2):121-30.

16. Amin A, Moustafa H, Ahmed E et al. Glioma residual or recurrence versus radiation necrosis: accuracy of pentavalent technetium-99m-dimercaptosuccinic acid [Tc-99m (V) DMSA] brain SPECT compared to proton magnetic resonance spectroscopy (1 H-MRS): initial results. J Neurooncol. 2012;106(3):579-87.

17. Sehweil AM, McKillop JH, Milroy R et al. Mechanism of 201Tl uptake in tumours. Eur J Nucl Med. 1989;15(7):376-9.

18. Sun D, Liu Q, Liu W et al. Clinical application of 201Tl SPECT imaging of brain tumors. J Nucl Med. 2000;41(1):5-10.

19. Matsunaga S, Shuto T, Takase H et al. Semiquantitative analysis using thallium-201 SPECT for differential diagnosis between tumor recurrence and radiation necrosis after gamma knife surgery for malignant brain tumors. Int J Radiat Oncol Biol Phys. 2013;85(1):47-52.

20. Nadeem Q, Khan I, Javed M, et al. Synthesis, characterization and bioevaluation of technetium-99m labeled N-(2-Hydroxybenzyl)-2-amino-2-deoxy-D-glucose as a tumor imaging agent. Pak J Pharm Sci. 2013;26(2):353-357.

21. Ono Y, Chernov MF, Muragaki Y et al. Imaging of Intracranial Gliomas. Prog Neurol Surg. 2018;30:12-62.

22. Jung JH, Ahn BC. Current Radiopharmaceuticals for Positron Emission Tomography of Brain Tumors. Brain Tumor Res Treat. 2018;6(2):47-53.

23. Larsson EM, Wikström J. Overview of neuroradiology. Handb Clin Neurol. 2017;145:579-599.

24. Herzog H, Van Den Hoff J. Combined PET/MR systems: an overview and comparison of currently available options. Q J Nucl Med Mol Imaging. 2012;56(3):247-67.

25. Palanichamy K, Chakravarti A. Diagnostic and Prognostic Significance of Methionine Uptake and Methionine Positron Emission Tomography Imaging in Gliomas. Front Oncol. 2017;7:257.

26. Dandois V, Rommel D, Renard L et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of treated high-grade gliomas: preliminary results in clinical practice. J Neuroradiol. 2010;37(2):89-97.

27. Sharma S. PET Radiopharmaceuticals for Personalized Medicine. Curr Drug Targets. 2016;17(16):1894-1907.

28. Ullrich RT, Kracht L, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med. 2009;50(12):1962-8.

29. Grosu AL, Weber WA, Riedel E et al. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63(1):64-74.

30. Jansen NL, Suchorska B, Wenter V et al. Dynamic 18F-FET PET in newly diagnosed astrocytic lowgrade glioma identifies high-risk patients. J Nucl Med. 2014;55(2):198-203.

31. Jansen NL, Suchorska B, Wenter V et al. Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma. J Nucl Med. 2015;56(1):9-15.

32. Albert NL, Winkelmann I, Suchorska B et al. Early static 18F-FET-PET scans have a higher accuracy for glioma grading than the standard 20–40 min scans. Eur J Nucl Med Mol Imaging. 2016;43(6):1105-14.

33. Langen KJ, Hamacher K, Weckesser M et al. O-(2-[18F] fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol. 2006;33(3):287-94.

34. Dunet V, Rossier C, Buck A et al. Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis. J Nucl Med. 2012;53(2):207-14.

35. Pöpperl G, Kreth FW, Mehrkens JH et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging. 2007;34(12):1933-42.

36. Harat M, Małkowski B, Makarewicz R. Preirradiation tumour volumes defined by MRI and dual time-point FET-PET for the prediction of glioblastoma multiforme recurrence: A prospective study. Radiother Oncol. 2016;120(2):241-7.

37. Galldiks N, Langen KJ, Holy R et al. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI. J Nucl Med. 2012;53(7):1048-57.

38. Demetriades AK, Almeida AC, Bhangoo RS et al. Applications of positron emission tomography in neurooncology: a clinical approach. Surgeon. 2014;12(3):148-57.

39. Fueger BJ, Czernin J, Cloughesy T et al. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med. 2010;51(10):1532-8.

40. Walter F, Cloughesy T, Walter MA et al. Impact of 3, 4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/ CT on managing patients with brain tumors: the referring physician’s perspective. J Nucl Med. 2012;53(3):393-8.

41. Chen W, Silverman DH, Delaloye S et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006;47(6):904-11.

42. Wardak M, Schiepers C, Cloughesy TF et al. 18 F-FLT and 18 F-FDOPA PET kinetics in recurrent brain tumors. Eur J Nucl Med Mol Imaging. 2014;41(6):1199-1209.

43. Yamamoto Y, Ono Y, Aga F et al. Correlation of 18F-FLT uptake with tumor grade and Ki-67 immunohistochemistry in patients with newly diagnosed and recurrent gliomas. J Nucl Med. 2012;53(12):1911-5.

44. Jonson SD, Welch MJ. Investigations into tumor accumulation and peroxisome proliferator activated receptor binding by F-18 and C-11 fatty acids. Nucl Med Biol. 2002;29(2):211-6.

45. Lam WW, Ng DC, Wong WY et al. Promising role of [18F] fluorocholine PET/CT vs [18F] fluorodeoxyglucose PET/CT in primary brain tumors—early experience. Clin Neurol Neurosurg. 2011;113(2):156-61.

46. Giovannini E, Lazzeri P, Milano A et al. Clinical applications of choline PET/CT in brain tumors. Curr Pharm Des. 2015;21(1):121-7.